Valerio Therapeutics SA banner

Valerio Therapeutics SA
PAR:ALVIO

Watchlist Manager
Valerio Therapeutics SA Logo
Valerio Therapeutics SA
PAR:ALVIO
Watchlist
Price: 0.143 EUR 0.7% Market Closed
Market Cap: €71.4m

Wall Street
Price Targets

ALVIO Price Targets Summary
Valerio Therapeutics SA

There are no price targets for ALVIO.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
Valerio Therapeutics SA Competitors:
Price Targets
MASI
Masimo Corp
3% Upside
HOTH
Hoth Therapeutics Inc
395% Upside
JACK
Jack in the Box Inc
46% Upside
VINP
Vinci Partners Investments Ltd
19% Upside

Revenue
Forecast

-4% / Year
Past Growth
247% / Year
Estimated Growth
Estimates Accuracy
6%
Average Beat
-4% / Year
Past Growth
247% / Year
Estimated Growth
Estimates Accuracy
6%
Average Beat

For the last 13 years the compound annual growth rate for Valerio Therapeutics SA's revenue is -4%. The projected CAGR for the next 2 years is 247%.

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-3%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-3%
Average Miss

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-91%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-91%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is ALVIO's stock price target?
Not Available

ALVIO doesn't have any price targets made by Wall Street professionals.

What is Valerio Therapeutics SA's Revenue forecast?
Projected CAGR
247%

For the last 13 years the compound annual growth rate for Valerio Therapeutics SA's revenue is -4%. The projected CAGR for the next 2 years is 247%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett